Lukasz Kuryk, VP Translational and Clinical Science, holds a PhD in biopharmaceutics/oncolytic virotherapy from University of Helsinki, Finland. He also earned his MBA diploma from the Institute of Computer Science PAN, Poland and Woodbury School of Business, UT, USA. Dr Kuryk brings experience in immuno-oncology and immuno-virotherapy, knowledge of preclinical, translational and early-stage clinical drug development in oncology (Phase I and II). Before joining Valo Therapeutics, he worked for last 10 years in clinical stage immuno-oncology companies Targovax (Director, Clinical Science) and Oncos Therapeutics (Research Scientist), on both pre-clinical research and clinical studies utilizing oncolytic vectors and peptide vaccines for cancer treatment. Mr Kuryk also worked at the Institute of Biomedical Research ‘’Alberto Sols’’, Spain, the Military Institute of Hygiene and Epidemiology, Poland. He was also a visiting researcher at the Regional WHO/Europe at the Robert Koch Institute, Germany, Bellvitge Biomedical Research Institute (IDIBELL), Spain, and University of Padova, Italy where conducing numerous research projects in the field of immuno-oncology and virology. Dr Kuryk is an Assistant Professor at the National Institute of Public Health, Poland, being responsible for several research projects in the field of immunotherapy. Lukasz is a Polish citizen and resides in Finland.
